|
DGAP-News: CytoTools AG
/ Key word(s): Personnel
Supervisory Board of CytoTools AG announces the retirement of the two members of the Management Board according to schedule Darmstadt, 30 September 2021 - The Supervisory Board of CytoTools AG (ISIN DE000A0KFRJ1) announces that the appointment of the two members of the Management Board of CytoTools AG, Dr. Mark-Andre Freyberg and Dr. Dirk Kaiser, will end by rotation on 30 September 2021. Following today's deselection by the Supervisory Board, both members of the Management Board are not available for a contract extension. Both members of the Management Board have therefore left the Company's Management Board today. The Supervisory Board very much regrets that Dr. Freyberg and Dr. Kaiser are not available for a further term of office due to the current situation and expresses its respect and high appreciation for their successful work over the past 15 years. Dr. Freyberg and Dr. Kaiser will remain closely associated with the Company as founders and shareholders. Contact: Disclaimer This release contains certain forward-looking statements. These reflect the views of CytoTools as of the date of this release. Actual results achieved by CytoTools may differ materially from the findings in the forward-looking statements. CytoTools is under no obligation to update any forward-looking statements.
30.09.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. |
| Language: | English |
| Company: | CytoTools AG |
| Klappacher Str. 126 | |
| 64285 Darmstadt | |
| Germany | |
| Phone: | +49 (0)6151-951 58 12 |
| Fax: | +49 (0)6151-951 58 13 |
| E-mail: | kontakt@cytotools.de |
| Internet: | www.cytotools.de |
| ISIN: | DE000A0KFRJ1 |
| WKN: | A0KFRJ |
| Listed: | Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt (Basic Board), Hamburg, Stuttgart, Tradegate Exchange |
| EQS News ID: | 1237234 |
| End of News | DGAP News Service |
|
|
1237234 30.09.2021
P R O D U C T S U G G E S T I O N S
The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.
The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.
If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.
For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.
1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.
